Patheon IncTSX: PTI

Patheon Unveils New Brand Image

· Issued by Patheon Inc via CNW

New Branding to be Launched at BIO2008 in San Diego This Week

TORONTO, June 17 /CNW/ - Patheon (TSX:PTI), a global provider of drug development and manufacturing services to the international pharmaceutical industry, is pleased to unveil its new brand image. The new brand features a new logo, new company colors and a new slogan that reflect Patheon's vision to become the best provider of manufacturing and development services to the pharmaceutical industry.

"We wanted our new brand to carry the foundation of the past and the promise for the future" said Terry Novak, President and Chief Marketing Officer, "therefore our name remains the same but the corporate colors, logo and slogan have been changed to reflect a new beginning and our commitment to continuous improvement."

Over the next few weeks Patheon will introduce the new brand in all of its 11 facilities around the world, and will develop a series of external promotions which more accurately reflect the company's broad range of services and future direction.

ABOUT PATHEON

Patheon Inc. (TSX:PTI; www.patheon.com) is a leading global provider of contract development and manufacturing services to the global pharmaceutical industry. Patheon prides itself in providing the highest quality products and services to more than 270 of the world's leading pharmaceutical and biotechnology companies. Patheon's services range from preclinical development through commercial manufacturing of a full array of dosage forms including parenteral, solid, semi-solid and liquid forms. Patheon uses many innovative technologies including single-use disposables, Liquid-Filled Hard Capsules and a variety of modified release technologies.

Patheon's comprehensive range of fully integrated Pharmaceutical Development Services includes pre-formulation, formulation, analytical development, clinical manufacturing, scale-up and commercialization. Patheon can take customers direct to clinic with global clinical packaging and distribution services and Patheon's Quick to Clinic(TM) programs can accelerate early phase development project to clinical trials while minimizing the consumption of valuable API.

Patheon's integrated development and manufacturing network of 11 facilities, and 6 development centers across North America and Europe, strives to ensure that customer products can be launched with confidence anywhere in the world.

Caution Concerning Forward-Looking Statements

This news release may contain forward-looking statements which reflect management's expectations regarding the Company's future growth of operations, performance (both operational and financial) and business prospects and opportunities. These statements are made in the context of the risks and uncertainties that are outlined in the Company's public documents, which can be accessed on our website at www.patheon.com or on SEDAR at www.sedar.com.

%SEDAR: 00001700E

Patheon Inc on 6ix

Earlier from Patheon

Later from Patheon

All Patheon news releases